Judicial biomarker accountability governance doctrine

Introduction

Judicial biomarker accountability governance doctrine refers to the emerging legal principles governing the use, interpretation, disclosure, and judicial oversight of biomarkers in healthcare, biotechnology, forensic science, and regulatory decision-making. A biomarker is a measurable biological characteristic that can indicate a physiological or pathological process, exposure, or response to treatment.

Examples include genetic variants, blood-based indicators, imaging markers, molecular signatures, and other measurable biological characteristics.

The expression is not presently a formally recognized independent legal doctrine. Rather, it can be understood as a proposed framework combining medical evidence law, privacy, informed consent, scientific reliability, administrative accountability, and judicial review. Its purpose is to ensure that biomarker evidence used by courts, regulators, hospitals, insurers, employers, or public authorities is scientifically reliable, lawfully obtained, properly interpreted, and subject to meaningful review.

Legal significance of biomarkers

Biomarkers can influence decisions concerning diagnosis, treatment, eligibility for clinical trials, disease risk, disability, insurance, employment, and forensic identification.

Because a biomarker may substantially influence a person's legal or medical status, errors can have serious consequences.

For example, a genetic biomarker may indicate an increased probability of developing a disease. It does not necessarily establish that the person currently has the disease. A court or regulator that treats probabilistic evidence as conclusive could therefore make an erroneous decision.

Judicial accountability requires courts and administrative bodies to distinguish between scientific association, probability, causation, and proof.

Scientific reliability

The first element of biomarker governance is scientific reliability.

Courts should consider:

• analytical validity;
• clinical validity;
• clinical utility;
• reproducibility;
• sensitivity;
• specificity;
• error rates;
• validation methodology;
• population limitations; and
• peer-reviewed scientific evidence.

A biomarker should not automatically become legally authoritative merely because it is technologically sophisticated.

Judicial scrutiny of scientific evidence

Courts frequently rely on expert testimony to interpret complex scientific evidence. However, judicial acceptance of scientific evidence generally requires some assessment of reliability.

In the United States, Daubert v Merrell Dow Pharmaceuticals, Inc. (1993) is a leading authority.

The U.S. Supreme Court held that trial judges have a gatekeeping role in determining whether expert scientific evidence is sufficiently reliable and relevant.

The Court identified considerations including whether a theory or technique can be tested, whether it has been subjected to peer review, its error rate, standards controlling its operation, and general acceptance.

These principles are highly relevant to biomarker evidence.

Daubert and biomarker evidence

Suppose a company claims that a new biomarker can predict an individual's response to a particular drug. If the company attempts to introduce the biomarker as decisive evidence in litigation, a court should examine whether the underlying methodology has been scientifically validated.

A biomarker based on a small experimental dataset should not automatically receive the same evidentiary weight as a clinically validated test.

The Daubert framework therefore supports judicial scrutiny of biomarker reliability.

General Electric v Joiner

In General Electric Co. v Joiner (1997), the U.S. Supreme Court emphasized that courts may scrutinize the connection between the expert's methodology and the conclusions reached.

This is especially relevant to biomarkers because statistically significant correlations do not necessarily establish causation.

For example, if a biomarker is associated with exposure to a chemical, that association alone may not prove that the chemical caused an individual's illness.

Kumho Tire v Carmichael

In Kumho Tire Co. v Carmichael (1999), the U.S. Supreme Court extended the judicial gatekeeping function beyond traditional scientific testimony to technical and specialized expert evidence.

The principle is useful for biomarker disputes because biomarker interpretation may involve medical science, statistics, computational biology, laboratory techniques, and specialized technology.

Biomarker evidence and causation

Causation is one of the most difficult issues.

A biomarker may establish:

• biological exposure;
• increased risk;
• association with disease;
• genetic predisposition; or
• response to treatment.

But these findings do not necessarily establish legal causation.

Courts must therefore distinguish between evidence that something occurred and evidence establishing why it occurred.

This distinction is particularly important in environmental litigation, pharmaceutical liability, occupational disease, and medical negligence cases.

Judicial accountability and genetic privacy

Biomarkers can contain highly sensitive genetic information.

In Justice K.S. Puttaswamy v Union of India (2017), the Supreme Court of India recognized privacy as a fundamental right and emphasized dignity, autonomy, and informational privacy.

Biomarker governance should therefore address how genetic and biological information is collected, stored, disclosed, and presented in judicial proceedings.

Courts may need to balance the evidentiary value of biomarker information against the individual's privacy rights.

S. and Marper v United Kingdom

In S. and Marper v United Kingdom (2008), the European Court of Human Rights considered the retention of fingerprints and DNA profiles.

The Court recognized significant privacy concerns associated with retaining biological identifiers.

The decision provides an important principle for judicial biomarker governance: biological information should not be retained or processed indefinitely merely because it might have future investigative value.

Biomarkers in forensic evidence

Biomarkers can also appear in forensic investigations.

DNA profiles are perhaps the most established example.

Courts may use DNA evidence to establish identity, biological relationships, or links between individuals and biological samples. However, proper collection, storage, laboratory methodology, contamination controls, and chain of custody are essential.

A scientifically reliable test can still produce legally unreliable evidence if the biological sample was improperly collected or contaminated.

R v Doheny and Adams

In R v Doheny and Adams (1997), the English Court of Appeal considered statistical interpretation of DNA evidence.

The case is important because it demonstrates the need for courts to explain DNA probabilities carefully and avoid presenting statistical evidence as absolute proof.

The same principle applies to biomarkers generally: probability must not be converted into certainty through misleading courtroom presentation.

R v T (2010)

In R v T, the UK Court of Appeal addressed the statistical interpretation of footwear evidence.

Although not a biomarker case, the judgment illustrates the broader judicial responsibility to handle statistical evidence carefully and avoid unsupported numerical claims.

This principle is particularly relevant when biomarker evidence is expressed through probabilities or risk ratios.

Biomarkers and informed consent

Clinical biomarker testing generally requires appropriate informed consent, particularly where results can reveal significant health or genetic information.

Patients should understand:

• what biomarker is being tested;
• why it is being tested;
• possible results;
• limitations of the test;
• implications for treatment;
• possible implications for relatives; and
• how the information will be stored or shared.

Failure to provide appropriate information may give rise to medical negligence or privacy concerns.

Montgomery v Lanarkshire Health Board

In Montgomery v Lanarkshire Health Board (2015), the UK Supreme Court emphasized the importance of patient-centered disclosure of material medical risks.

The case is relevant to biomarker governance because a biomarker may affect significant treatment decisions. Patients should have meaningful information about material risks and reasonable alternatives where biomarker results influence clinical care.

Biomarkers and regulatory governance

Biomarkers can also be used by regulators to determine whether drugs are effective or safe.

A biomarker may serve as a surrogate endpoint in clinical research.

However, a surrogate endpoint does not necessarily guarantee that improvement in the biomarker translates into improved patient outcomes.

Judicial governance therefore requires regulators to maintain transparent standards concerning validation and evidentiary weight.

Administrative judicial review

When a government agency relies heavily on biomarker evidence, courts may review whether the agency:

• acted within statutory authority;
• relied on relevant evidence;
• ignored material evidence;
• followed procedural requirements;
• provided adequate reasons; and
• acted irrationally or disproportionately.

Judicial review does not ordinarily mean that judges substitute their own scientific opinions for those of specialized regulators. Instead, courts examine whether the decision-making process was lawful and rational.

Accountability for AI-generated biomarkers

Modern AI systems can identify potential biomarkers from large genomic or medical datasets.

This creates additional accountability concerns.

An AI system may identify a statistical association that researchers cannot easily explain. Before such a biomarker is used in clinical or judicial decision-making, there should be validation and independent assessment.

Responsibility should remain with the institution deploying the system rather than being transferred to the algorithm.

Discrimination concerns

Biomarkers may reveal predispositions to diseases or other biological characteristics.

Using such information to deny employment, insurance, education, or other opportunities could create discrimination concerns.

Governance frameworks should therefore distinguish legitimate medical use from inappropriate social profiling.

Chain of custody and data integrity

For judicial use, biomarker evidence requires strong chain-of-custody procedures.

Courts should be able to determine:

1. where the sample came from;
2. who collected it;
3. how it was transported;
4. who tested it;
5. which methodology was used;
6. whether quality controls were satisfied; and
7. whether the result was altered or compromised.

Digital biomarker records also require protection against unauthorized alteration.

Remedies for biomarker error

Where unreliable biomarker evidence causes legal or medical harm, possible remedies may include:

• exclusion of unreliable evidence;
• reconsideration of an administrative decision;
• compensation;
• correction of medical records;
• destruction or restriction of improperly retained data;
• disciplinary action; and
• judicial review.

The appropriate remedy depends on the nature of the harm and the applicable legal system.

Conclusion

Judicial biomarker accountability governance doctrine is an emerging framework rather than an established standalone legal doctrine. It seeks to ensure that biomarker evidence used in judicial, medical, regulatory, and administrative decisions is scientifically reliable, properly interpreted, lawfully obtained, privacy-protective, and subject to meaningful judicial scrutiny.

The cases Daubert v Merrell Dow Pharmaceuticals, General Electric v Joiner, Kumho Tire v Carmichael, R v Doheny and Adams, S. and Marper v United Kingdom, Puttaswamy v Union of India, and Montgomery v Lanarkshire Health Board provide important principles concerning scientific reliability, statistical evidence, genetic privacy, expert testimony, and informed medical decision-making.

The central principle is that biological evidence should inform legal decision-making without becoming immune from legal scrutiny. Courts should distinguish correlation from causation, probability from certainty, and scientific sophistication from scientific validity. As AI, genomics, and precision medicine produce increasingly complex biomarkers, robust judicial oversight will be essential to prevent unreliable biological evidence from producing unjust legal or medical consequences.